A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ 333369 as Adjunctive Therapy in Subjects With Partial Onset Seizures Followed by an Open-Label Extension Study: Open-Label Extension Period

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ 333369 as Adjunctive Therapy in Subjects With Partial Onset Seizures Followed by an Open-Label Extension Study: Open-Label Extension Period

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2013

At a glance

  • Drugs Carisbamate (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; Registrational
  • Sponsors SK Life Science
  • Most Recent Events

    • 23 Jun 2011 New source identified and integrated (European Clinical Trials Database).
    • 18 Nov 2010 Status changed from active, no longer recruiting to completed, according to the ClinicalTrials.gov record.
    • 30 Sep 2010 Planned end date changed from 1 Dec 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top